Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Markets

Trump’s Tariff Threats Target Big Pharma, But Tax Reforms May Hold the Key to U.S. Manufacturing Growth

by Team Lumida
May 7, 2025
in Markets
Reading Time: 5 mins read
A A
0
Fed Official Warns of Inflation Risks Under Trump Presidency

"Donald Trump" by Gage Skidmore is licensed under CC BY-SA 2.0

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • President Trump’s proposed tariffs on the pharmaceutical industry aim to bring more drug production back to the U.S., but experts argue that tax reforms could be a more effective long-term solution.
  • Pharma companies historically moved offshore not for cheap labor but to benefit from lower corporate tax rates in countries like Ireland, which offered a 12.5% rate compared to the U.S.’s pre-2017 rate of 35%.
  • Trump’s 2017 tax reforms, which lowered the U.S. corporate tax rate to 21% and introduced a minimum tax on foreign earnings, have already made U.S. production more attractive.
  • Industry leaders, including CEOs from Eli Lilly, Pfizer, and Johnson & Johnson, are pushing for further tax incentives, such as a 15% tax rate for U.S. manufacturing, restored R&D deductions, and more favorable interest deductions for domestic facility investments.
  • Generic drug production, which has largely shifted to India and China, poses a unique challenge due to its low margins. Tariffs on generics could worsen drug shortages and quality issues in the U.S.

What Happened?

President Trump’s administration is ramping up pressure on the pharmaceutical industry with proposed tariffs aimed at reshoring drug production. While tariffs have prompted some companies to expand U.S. operations, experts argue that tax reforms would be a more sustainable way to encourage long-term investment.

Pharma companies have historically moved operations offshore to benefit from lower tax rates, not cheaper labor. Trump’s 2017 tax reforms reduced the corporate tax rate and introduced measures like the Global Intangible Low-Taxed Income (GILTI) regime, which taxed foreign earnings. However, loopholes still allow companies to report U.S.-generated profits in low-tax jurisdictions.

Congress is now considering additional tax incentives, such as a 15% tax rate for U.S. manufacturing and restored R&D deductions, to further boost domestic production. At the same time, policymakers are exploring ways to tighten GILTI rules to ensure they apply only to genuinely foreign profits.


Why It Matters?

The pharmaceutical industry is one of the few sectors where reshoring is feasible due to its high margins and reliance on intellectual property rather than cheap labor. However, tariffs alone may not be enough to drive meaningful change.

Tax reforms, such as lowering the tax rate for U.S. manufacturing and restoring R&D incentives, could provide a more effective and sustainable framework for reshoring. These measures would not only encourage investment but also ensure that profits are reported and taxed in the U.S.

For generic drug production, which has largely moved to India and China, tariffs could exacerbate existing issues like drug shortages and quality concerns. Direct financial support from the government may be necessary to bring portions of this industry back to the U.S.


What’s Next?

Pharma companies have already announced significant U.S. investments, with Eli Lilly, Roche, and Johnson & Johnson pledging a combined $132 billion to expand domestic operations. However, the sustainability of these investments will depend on whether Congress enacts further tax reforms.

Policymakers will also need to address the unique challenges of the generic drug industry, potentially through targeted financial support or incentives. The outcome of these efforts will shape the future of U.S. pharmaceutical manufacturing and its ability to compete globally.

Source
Previous Post

SEC Delays Decision on Litecoin ETF, Requests Public Comments

Next Post

Mark Zuckerberg Envisions a Future Where AI Friends Outnumber Human Companions

Recommended For You

S&P 500 and Dow Close in Correction, Nasdaq Drops 5.28% and Erases Its 2026 Gain as the AI Rout Deepens

by Team Lumida
2 days ago

The S&P 500 fell 3.7% into a correction and the Nasdaq dropped 5.28%, turning negative for 2026, in a brutal week for the AI trade.

Read more

Nasdaq 100 Futures Jump 2% and S&P 500 Futures 1.1% as Anthropic’s Above-Range IPO Revives the AI Trade After the S&P 500’s Fifth Straight Loss

by Team Lumida
4 days ago

US stock futures jumped early Thursday as Anthropic’s $83 IPO pricing lifted AI sentiment, after the S&P 500 fell for a fifth straight session.

Read more

Dow Drops 426 Points as Nvidia’s Post-Earnings Bounce Fizzles, With CoreWeave Down 6%, Nebius 4% and Iren 3% as Neoclouds Reverse Early Gains

by Team Lumida
4 days ago

The Dow fell 426 points as Nvidia gave up its post-earnings gains, while CoreWeave, Nebius and Iren reversed early premarket jumps.

Read more

Wall Street Expects Global Earnings Growth to Halve to 16% in 2027 From 33.5%, With Goldman Seeing US Profit Growth Falling From 36% to 11% as AI Capex Growth Peaks in the First Half

by Team Lumida
5 days ago

Analysts expect MSCI ACWI earnings growth to slow to 16% in 2027 from 33.5%, and Goldman sees US profit growth falling to 11% from 36%, the FT reports.

Read more

Dow Falls 760 Points as Chip Stocks Slide Into Nvidia Earnings, With Micron Down 6% and Nvidia on Pace for Its Worst Month Since April 2022

by Team Lumida
5 days ago
BlackRock’s Larry Fink on Economic Growth and Market Misconceptions

The Dow fell 760 points as chipmakers slid ahead of Nvidia earnings, with Micron down about 6% and Nvidia off 26% this month.

Read more

Deutsche Bank Flagged $582 Million of Suspicious Epstein-Linked Payments in US Filings and Once Mistakenly Sent Out Trump’s Tax Statements, Leaked Documents Show

by Team Lumida
6 days ago

Leaked documents show Deutsche Bank filed US suspicious activity reports on $582 million of Epstein-linked transfers and once mistakenly sent Trump’s tax statements.

Read more

S&P 500 Sinks 1.92% and Nasdaq 2.49% for a Third Straight Loss as Nvidia Drops 4.1%, With Futures Mixed Hours Before Its Earnings

by Team Lumida
6 days ago

US stocks fell for a third day as Nvidia slid 4.1%, with the VIX jumping and futures mixed ahead of Nvidia’s results and retail sales data.

Read more

BlackRock Triples Its Equity Overweight to 3% and Broadens AI Bets in Its $300 Billion Model Portfolios, Pulling About $4.4 Billion From Its Treasury ETF

by Team Lumida
6 days ago
Is BlackRock the New Leader in Alternative Investments?

BlackRock lifted its equity overweight to 3% from 1% and broadened AI exposure in its $300 billion model portfolios, driving billions in ETF flows.

Read more

Nasdaq-100 Futures Drop 0.77% and SK Hynix Sinks 5.6% as Markets Brace for Nvidia’s First Post-Huang Earnings and Anthropic’s IPO

by Team Lumida
7 days ago
AI Bulls Trample Bond Market Warnings — S&P 500 Breaks 7,800 as Tech Rally Defies Elevated Yields, Fed Uncertainty, Global Tightening

US stock futures slipped and Asian chipmakers slid as investors braced for Nvidia's earnings and Anthropic's roughly $1.4 trillion IPO.

Read more

Nvidia’s 2031 Bond Yield Rises to 5.717% After Huang’s Exit, With $36 Billion of Neocloud Backstops Now Under Scrutiny

by Team Lumida
1 week ago

Nvidia’s 4.5% bond due 2031 yielded 5.717% on Friday, and analysts are questioning the company’s role in backing AI infrastructure after Jensen Huang’s exit.

Read more
Next Post
a white square with a blue logo on it

Mark Zuckerberg Envisions a Future Where AI Friends Outnumber Human Companions

China’s Bold Economic Moves: What You Need to Know Now

China Cuts Rates and Injects $139 Billion in Liquidity to Counter U.S. Tariffs

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

blue and red cargo ship on sea during daytime

Hormuz Deal Unravels — Ship Struck Off Oman as Talks Bog Down Over Fees, Oil Prices Reverse Higher

August 4, 2026
BitGo’s IPO Raises $212.8 Million, Valuing Crypto Custodian at $2.2 Billion

BitGo’s IPO Raises $212.8 Million, Valuing Crypto Custodian at $2.2 Billion

January 23, 2026
Big Tech Uses $300B in Residual Value Guarantees to Keep AI Exposure Off Balance Sheets; Meta, Nvidia, Broadcom Lock in Infrastructure Financing

Big Tech Uses $300B in Residual Value Guarantees to Keep AI Exposure Off Balance Sheets; Meta, Nvidia, Broadcom Lock in Infrastructure Financing

September 21, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018